Hansa Biopharma Investor Relations Material

Hansa Biopharma AB, a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. It develops recombinant IgG endopeptidase/CD26 in Hx-CD26 for IgG-mediated autoimmune indications; and antibody drug conjugates (ADCs) in hu2m14 that targets EGF receptor mutations. The company also develops ADCs against CD56 positive cancers in naxitamab; and multiple bispecific antibodies to meet the needs of the various target populations across hematological cancers under pre-clinical development program. In addition, it involves in developing enzyme platform technology to facilitate the development of antibody therapies by inhibiting unwanted immune reactions; and facilitates bone marrow transplantation between genetically distinct individuals.